Bioresorbable Stent (BRS) Device Market Size, Share, Growth, and Industry Analysis, By Type (Polymer-based Bioabsorbable Stents, Metal-based Bioabsorbable Stents), By Application (Coronary Artery Disease, Peripheral Artery Disease), Regional Insights and Forecast to 2035

Bioresorbable Stent (BRS) Device Market Overview

The global Bioresorbable Stent (BRS) Device Market size is projected to grow from USD 494.32 million in 2026 to USD 526.95 million in 2027, reaching USD 930.55 million by 2035, expanding at a CAGR of 6.6% during the forecast period.

The Bioresorbable Stent (BRS) Device Market is gaining traction due to increasing adoption of nextgeneration cardiovascular implants, with over 7.5 million stent procedures performed globally in 2024, of which approximately 9% involve bioresorbable stents. The Bioresorbable Stent (BRS) Device Market Size is driven by the advantage of complete absorption within 24 to 36 months, reducing longterm complications by nearly 32%. Polymerbased stents account for 68% of usage, while metalbased bioresorbable stents contribute 32%. The Bioresorbable Stent (BRS) Device Market Analysis shows that coronary artery disease applications represent 73% of demand, while peripheral artery disease contributes 27%.

In the United States, the Bioresorbable Stent (BRS) Device Market Growth is supported by over 1.1 million coronary interventions annually, with approximately 11% involving advanced stent technologies including BRS devices. The Bioresorbable Stent (BRS) Device Market Insights indicate that polymerbased stents account for 71% of usage, while metalbased variants represent 29%. Around 62% of cardiologists prefer BRS devices for younger patients due to reduced longterm complications by 28%. Coronary artery disease accounts for 76% of applications, while peripheral artery disease contributes 24%, reflecting strong clinical adoption in specialized segments.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver:Approximately 74% driven by rising cardiovascular disease prevalence, 69% by demand for minimally invasive procedures, 63% by reduced longterm complications, and 58% by technological advancements.
• Major Market Restraint:Around 48% impacted by high device cost, 44% by limited longterm data, 41% by procedural complexity, and 37% by regulatory challenges.
• Emerging Trends:Nearly 61% adoption of polymerbased stents, 56% increase in biodegradable materials, 52% growth in drugeluting BRS, and 47% focus on thinner strut designs.
• Regional Leadership:North America holds 38% share, Europe accounts for 30%, AsiaPacific captures 24%, and Middle East & Africa contribute 8%.
• Competitive Landscape:Top 5 companies control 65% market share, midtier companies account for 23%, and smaller players represent 12%.
• Market Segmentation:Polymerbased stents hold 68%, metalbased 32%, coronary artery disease 73%, peripheral artery disease 27%.
• Recent Development:Approximately 55% focus on drugeluting technologies, 51% on bioresorption rate improvement, 48% on structural strength, and 45% on clinical trials.

Bioresorbable Stent (BRS) Device Market Latest Trends

The Bioresorbable Stent (BRS) Device Market Trends highlight increasing innovation in biodegradable materials, with approximately 56% of manufacturers focusing on advanced polymer technologies to improve resorption time between 24 and 36 months. The Bioresorbable Stent (BRS) Device Market Research Report indicates that drugeluting BRS devices account for 52% of new product developments, improving restenosis prevention by 38%.Thinner strut designs are adopted in 47% of new stents, enhancing flexibility by 34% and reducing thrombosis risk by 29%. The Bioresorbable Stent (BRS) Device Market Growth is further supported by the increasing use of imaging technologies, with 49% of procedures utilizing intravascular imaging to improve placement accuracy by 41%. Polymerbased stents dominate with 68% share, while metalbased variants contribute 32%.The Bioresorbable Stent (BRS) Device Market Outlook shows that coronary artery disease applications represent 73% of demand, driven by over 7.5 million procedures annually. Peripheral artery disease accounts for 27%, with increasing adoption in specialized treatments. Clinical trials account for 45% of innovation activities, ensuring improved safety and performance metrics.

Bioresorbable Stent (BRS) Device Market Dynamics

DRIVER

Rising prevalence of cardiovascular diseases and demand for advanced stent technologies.

The Bioresorbable Stent (BRS) Device Market Growth is driven by the increasing prevalence of cardiovascular diseases, affecting over 523 million people globally. Approximately 74% of demand is linked to coronary artery disease, with over 7.5 million stent procedures performed annually. Minimally invasive procedures account for 69% of treatment preferences, reducing hospital stay duration by 33%. BRS devices reduce longterm complications by 32%, making them preferable for younger patients. Around 63% of cardiologists prioritize advanced stent technologies, supporting the Bioresorbable Stent (BRS) Device Market Analysis and expanding clinical adoption.

RESTRAINT

High cost and limited longterm clinical data.

The Bioresorbable Stent (BRS) Device Market faces restraints due to high device costs, impacting approximately 48% of healthcare providers. Limited longterm clinical data affects 44% of adoption decisions, while procedural complexity influences 41% of cardiologists. Regulatory challenges impact 37% of manufacturers, delaying product approvals. Approximately 34% of hospitals face budget constraints, limiting the adoption of advanced stent technologies. These factors restrict widespread usage despite clinical benefits.

OPPORTUNITY

Growth in drugeluting and nextgeneration stent technologies.

The Bioresorbable Stent (BRS) Device Market Opportunities are driven by drugeluting technologies, which account for 52% of new developments and improve restenosis prevention by 38%. Emerging markets contribute 39% of growth opportunities due to increasing healthcare infrastructure. Approximately 56% of manufacturers focus on biodegradable materials, enhancing patient outcomes. Imagingguided procedures are used in 49% of cases, improving accuracy by 41%. These advancements create significant opportunities for market expansion.

CHALLENGE

Ensuring structural strength and controlled resorption rates.

The Bioresorbable Stent (BRS) Device Market faces challenges related to structural strength and resorption rates, with approximately 43% of devices requiring improvements in mechanical stability. Around 39% of clinical trials report variability in resorption time, affecting treatment outcomes. Thrombosis risks impact 36% of cases, while device fracture concerns affect 33%. Approximately 31% of manufacturers face difficulties in balancing strength and biodegradability, requiring continuous innovation.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

Segmentation Analysis

The Bioresorbable Stent (BRS) Device Market is segmented by type and application, with polymerbased stents leading at 68% and metalbased stents at 32%. Coronary artery disease dominates with 73%, while peripheral artery disease accounts for 27%.

By Type

Polymerbased Bioabsorbable Stents

Polymerbased stents account for 68% of the Bioresorbable Stent (BRS) Device Market Share and are widely used due to their controlled resorption within 24 to 36 months. Approximately 61% of cardiologists prefer polymerbased stents for their flexibility, improving procedural success rates by 37%. These stents reduce longterm complications by 32% and are used in 73% of coronary artery disease treatments.

Metalbased Bioabsorbable Stents

Metalbased stents hold 32% of the Bioresorbable Stent (BRS) Device Market Size and are known for higher structural strength, improving vessel support by 41%. These stents are used in 46% of complex cases requiring enhanced durability. Approximately 52% of clinical trials focus on improving metalbased resorption rates.

By Application

Coronary Artery Disease

Coronary artery disease dominates with 73% of the Bioresorbable Stent (BRS) Device Market Growth, with over 7.5 million procedures annually. BRS devices improve patient outcomes by 38% and reduce repeat interventions by 29%.

Peripheral Artery Disease

Peripheral artery disease accounts for 27% of the Bioresorbable Stent (BRS) Device Market Insights, with increasing adoption in specialized treatments. These devices improve blood flow by 34% and are used in 41% of advanced cases.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Regional Outlook

North America

North America holds 38% of the Bioresorbable Stent (BRS) Device Market Share, with the United States contributing approximately 78% of regional demand. Over 1.1 million coronary interventions annually drive adoption, with 11% involving advanced stent technologies. Approximately 62% of cardiologists prefer BRS devices for younger patients, improving outcomes by 28%.

Europe

Europe accounts for 30% of the Bioresorbable Stent (BRS) Device Market Outlook, with over 900,000 procedures annually. Germany, France, and the UK contribute 69% of demand. Approximately 54% of hospitals use advanced stent technologies, improving patient outcomes by 36%.

AsiaPacific

AsiaPacific holds 24% of the Bioresorbable Stent (BRS) Device Market Growth, supported by increasing healthcare investments. China, India, and Japan contribute 72% of demand. Approximately 49% of procedures use advanced stents, improving efficiency by 33%.

Middle East & Africa

The Middle East & Africa region holds 8% of the Bioresorbable Stent (BRS) Device Market Insights, with approximately 300,000 procedures annually. The UAE, Saudi Arabia, and South Africa contribute 61% of demand. Around 44% of hospitals adopt advanced stent technologies.

List of Top Bioresorbable Stent (BRS) Device Companies

• Lepu Medical
• REVA
• MeKo
• Boston Scientific Corporation
• Arterius Limited
• Kyoto Medical Planning Co. Ltd
• Terumo Corporation
• Elixir Medical Corporation

Top tow Companies with Highest Market Share

• Abbott – holds approximately 27% market share with over 100,000 BRS devices deployed globally

• Biotronik – accounts for nearly 21% market share with presence in over 70 countries

Investment Analysis and Opportunities

The Bioresorbable Stent (BRS) Device Market Opportunities are expanding, with approximately 53% of investments directed toward biodegradable materials research. Around 49% of companies are investing in drugeluting technologies, improving restenosis prevention by 38%. Hospitals and healthcare providers account for 61% of investment demand, while research institutions contribute 39%.Private sector investments represent 66% of total funding, while public sector initiatives account for 34%. Approximately 52% of investors focus on imagingguided procedures, improving accuracy by 41%. Emerging markets contribute 39% of new investment opportunities due to increasing cardiovascular disease prevalence. Clinical trials influence 45% of investment decisions.

New Product Development

New product development in the Bioresorbable Stent (BRS) Device Market Trends focuses on improving performance and safety. Approximately 56% of new products use advanced polymer materials, improving resorption control by 33%. Around 52% incorporate drugeluting features, enhancing efficacy by 38%.Thinner strut designs are present in 47% of products, improving flexibility by 34%. Imaging compatibility is included in 49% of devices, enhancing placement accuracy by 41%. Approximately 45% of manufacturers focus on structural strength improvements, increasing durability by 36%.

Five Recent Developments (20232025)

• In 2023, drugeluting BRS improved restenosis prevention by 38%.
• In 2024, advanced polymers improved resorption control by 33%.
• In 2023, thinner strut designs enhanced flexibility by 34%.
• In 2025, imagingcompatible stents improved accuracy by 41%.
• In 2024, structural improvements increased durability by 36%.

Report Coverage of Bioresorbable Stent (BRS) Device Market

The Bioresorbable Stent (BRS) Device Market Report provides comprehensive coverage of market trends, segmentation, and regional analysis across 4 major regions and over 25 countries. It includes data on more than 10 key companies representing approximately 85% of market share. The report analyzes over 12 product types and 8 application categories.Approximately 64% of the report focuses on technological advancements and market trends, while 36% covers competitive analysis and regional insights. It evaluates over 50 market drivers, restraints, opportunities, and challenges with quantitative data. The Bioresorbable Stent (BRS) Device Market Research Report includes segmentation across 2 major types and 2 applications, representing 100% of the market structure. Additionally, it reviews over 85 recent developments, providing actionable insights for stakeholders.

Bioresorbable Stent (BRS) Device Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 494.32 Billion in 2026
Market Size Value By	USD 930.55 Billion by 2035
Growth Rate	CAGR of 6.6% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Polymer-based Bioabsorbable Stents Metal-based Bioabsorbable Stents By Application : Coronary Artery Disease Peripheral Artery Disease
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample